Syndax Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Syndax Pharmaceuticals
SNDX Stock  USD 19.30  0.03  0.16%   
Syndax Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Syndax Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Syndax Pharmaceuticals financial statements helps investors assess Syndax Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Syndax Pharmaceuticals' valuation are summarized below:
Gross Profit
139.7 M
Market Capitalization
1.7 B
Enterprise Value Revenue
8.9974
Revenue
126.6 M
Earnings Share
(3.24)
We have found one hundred twenty available fundamental trend indicators for Syndax Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Syndax Pharmaceuticals current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 1.6 B in 2024. Enterprise Value is likely to rise to about 1.3 B in 2024

Syndax Pharmaceuticals Total Revenue

126.58 Million

Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.4 K, Interest Expense of 197.6 K or Selling General Administrative of 57.1 M, as well as many indicators such as Price To Sales Ratio of 6.97, Dividend Yield of 0.0 or PTB Ratio of 2.88. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Syndax Pharmaceuticals Correlation against competitors.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Syndax Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets643.5 M612.9 M201.5 M
Slightly volatile
Short and Long Term Debt Total1.6 M1.6 M9.5 M
Slightly volatile
Other Current Liabilities843.6 K888 K3.6 M
Slightly volatile
Total Current Liabilities61 M58.1 M22.8 M
Slightly volatile
Property Plant And Equipment Net1.6 M1.5 M532.3 K
Slightly volatile
Current Deferred Revenue47.1 M44.8 M11.1 M
Slightly volatile
Accounts Payable18.1 M17.2 M4.4 M
Slightly volatile
Cash310.2 M295.4 M78.6 M
Slightly volatile
Non Current Assets Total33.6 M32 M6.5 M
Slightly volatile
Non Currrent Assets Other646 K680 K1.4 M
Pretty Stable
Cash And Short Term Investments606.5 M577.6 M192.9 M
Slightly volatile
Common Stock Shares Outstanding38.8 M70.4 M40.1 M
Very volatile
Short Term Investments296.3 M282.2 M114.2 M
Slightly volatile
Liabilities And Stockholders Equity643.5 M612.9 M201.5 M
Slightly volatile
Non Current Liabilities Total558.6 K588 K10.5 M
Very volatile
Other Current Assets59.9 K63 K374.9 K
Very volatile
Other Stockholder Equity1.5 B1.5 B503.8 M
Slightly volatile
Total Liabilities34.5 M58.7 M31.5 M
Slightly volatile
Property Plant And Equipment Gross2 M1.9 M644.6 K
Slightly volatile
Total Current Assets609.9 M580.9 M194.9 M
Slightly volatile
Short Term Debt994.6 K1 M7.7 M
Slightly volatile
Common Stock Total Equity7.2 K6.9 K3.1 K
Slightly volatile
Common Stock8.4 K8 K3.3 K
Slightly volatile
Other Liabilities14.2 M13.4 M9.6 M
Slightly volatile
Long Term Debt12.4 M22.9 M13.4 M
Slightly volatile
Net Receivables795.6 K1.2 M544.6 K
Slightly volatile
Deferred Long Term Liabilities20.2 M19.3 M10.5 M
Slightly volatile
Short and Long Term Debt2.1 M2.6 M2 M
Slightly volatile
Preferred Stock Total Equity264.2 M375.3 M268 M
Slightly volatile
Property Plant Equipment1.3 M1.2 M411.7 K
Slightly volatile
Capital Surpluse669.6 M1.1 B580.3 M
Slightly volatile
Non Current Liabilities Other776.8 K817.6 K1.1 M
Pretty Stable
Net Invested Capital300.3 M554.2 M196.1 M
Slightly volatile
Net Working Capital301.7 M522.8 M203 M
Slightly volatile
Capital Stock5.7 K8 K3.5 K
Slightly volatile
Capital Lease Obligations1.1 M1.6 M959.7 K
Slightly volatile
Long Term Debt Total20.8 M22.9 M18.6 M
Slightly volatile

Syndax Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization11.4 K12 K45 K
Very volatile
Selling General Administrative57.1 M54.3 M19.6 M
Slightly volatile
Other Operating Expenses241.5 M230 M75.5 M
Slightly volatile
Research Development171.2 M163 M54.2 M
Slightly volatile
Total Operating Expenses241.4 M229.9 M75.5 M
Slightly volatile
Interest Income19.5 M18.6 M4 M
Slightly volatile
Reconciled Depreciation11.4 K12 K64.4 K
Slightly volatile

Syndax Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation32.5 M31 M8.8 M
Slightly volatile
Begin Period Cash Flow52.9 M74.5 M42.5 M
Slightly volatile
Other Cashflows From Financing Activities5.7 M6 M40.4 M
Pretty Stable
Depreciation11.4 K12 K45 K
Very volatile
Total Cash From Financing Activities277.3 M264.1 M95.9 M
Slightly volatile
End Period Cash Flow310.4 M295.6 M78.7 M
Slightly volatile
Sale Purchase Of Stock27.1 M28.6 M40.2 M
Pretty Stable
Change To Netincome8.2 M16.1 M6.3 M
Slightly volatile
Dividends Paid2.1 M2.3 M2.5 M
Slightly volatile
Issuance Of Capital Stock137.9 M162.4 M67.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.977.34204
Slightly volatile
Days Sales Outstanding1.221.2979.5744
Slightly volatile
Stock Based Compensation To Revenue0.10.113.8673
Slightly volatile
EV To Sales5.746.05179
Slightly volatile
Payables Turnover7.0E-47.0E-40.0714
Slightly volatile
Sales General And Administrative To Revenue0.20.2111.1301
Slightly volatile
Research And Ddevelopement To Revenue0.690.7316.2728
Slightly volatile
Cash Per Share8.628.20774.4662
Slightly volatile
Days Payables Outstanding549.1 K523 K75.3 K
Slightly volatile
Income Quality0.630.76710.798
Pretty Stable
Current Ratio7.759.99868.2721
Slightly volatile
Receivables Turnover30829386.9384
Slightly volatile
Graham Number24.1122.960411.7017
Slightly volatile
Revenue Per Share2.542.420.7249
Slightly volatile
Interest Debt Per Share0.02490.02620.4614
Slightly volatile
Debt To Assets0.00250.00273.0018
Slightly volatile
Days Of Payables Outstanding549.1 K523 K75.3 K
Slightly volatile
Ebt Per Ebit1.170.91041.0778
Slightly volatile
Long Term Debt To Capitalization0.0010.00111.454
Slightly volatile
Quick Ratio7.669.9638.1698
Slightly volatile
Net Income Per E B T1.091.111.0072
Slightly volatile
Cash Ratio2.795.08462.9833
Slightly volatile
Days Of Sales Outstanding1.221.2979.5744
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0186
Slightly volatile
Fixed Asset Turnover10599.7132.6712
Slightly volatile
Debt Ratio0.00250.00273.0018
Slightly volatile
Price Sales Ratio6.977.34204
Slightly volatile
Asset Turnover0.290.280.0871
Slightly volatile
Gross Profit Margin0.80.90.9772
Slightly volatile
Operating Cycle4.9 K5.5 K6 K
Slightly volatile
Cash Conversion Cycle1.3 K1.4 K1.6 K
Slightly volatile

Syndax Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.6 B1.5 B534.7 M
Slightly volatile
Enterprise Value1.3 B1.2 B452.7 M
Slightly volatile

Syndax Fundamental Market Drivers

Cash And Short Term Investments577.6 M

Syndax Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Syndax Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Syndax Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Syndax Pharmaceuticals investors use historical funamental indicators, such as Syndax Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Syndax Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Syndax Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Syndax Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Syndax Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue44.8 M47.1 M
Total Revenue126.6 M0.0
Cost Of Revenue12 K11.4 K
Stock Based Compensation To Revenue 0.11  0.10 
Sales General And Administrative To Revenue 0.21  0.20 
Research And Ddevelopement To Revenue 0.73  0.69 
Capex To Revenue(0.0008)(0.0009)
Revenue Per Share 2.42  2.54 
Ebit Per Revenue 0.17  0.18 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
MSFTMicrosoft
CRMSalesforce
GOOGAlphabet Inc Class C

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY